A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen

Pfizer1 site in 1 country179 target enrollmentAugust 2002

ConditionsHuman Immunodeficiency Virus

DrugsCapravirine

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Human Immunodeficiency Virus
Sponsor: Pfizer
Enrollment: 179
Locations: 1
Primary Endpoint: The primary objective was to determine whether the addition of capravirine to a regimen of VIRACEPT and 2 new nucleoside reverse transcriptase inhibitors would provide a higher virologic response rate over 48 weeks
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.

Registry

clinicaltrials.gov

Start Date

August 2002

End Date

November 2004

Last Updated

14 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Pfizer

Eligibility Criteria

Inclusion Criteria

•Male or female at least 18 years old
•HIV RNA level \>1000 copies/mL at screening
•CD4 \>50 cells/uL at screening
•Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen
•Patient has adequate hematology tests (absolute neutrophil count \>1000/uL, Platelets\>75,000uL, hemoglobin 9g/L)
•Patient has adequate renal function (serum creatinine of \<1.5 upper limit of normal)
•Patient has adequate liver function (AST, ALT, and bilirubin \< 2.5 upper limit of normal)

Exclusion Criteria

•Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was \<50 copies) This exception does not include Viracept
•Women who are pregnant or lactating

Outcomes

Primary Outcomes

The primary objective was to determine whether the addition of capravirine to a regimen of VIRACEPT and 2 new nucleoside reverse transcriptase inhibitors would provide a higher virologic response rate over 48 weeks

when compared to a 3-drug regimen without capravirine in patients who had experienced virologic failure while on a nonnucleoside reverse transcriptase inhibitor regimen.

Secondary Outcomes

The safety and tolerability of 2 doses of capravirine.
The difference between 2 doses of capravirine in terms of tolerability, efficacy, and pharmacokinetics
The relationship of HIV resistance (genotype and phenotype) to virologic response.
The immunologic response as determined by CD4 and CD8 absolute lymphocyte counts
The population pharmacokinetics of capravirine and VIRACEPT
The pharmacokinetics of potential drug-drug interactions.